Video
ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodg...
Dr Paul Bröckelmann - University of Cologne, Cologne, Germany
Lack of access to new cancer medicines in LMICs
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Spotlight on global cancer control at ASCO 2022
Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM
ASCO 2022: Head and neck cancer highlights
Dr Mark Persky - NYU Langone’s Perlmutter Cancer Center, New York, USA
UICC announces global coalition to increase access to essential cancer medicines...
Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control
Biomarker guidance allows patients 55 or older with low-grade luminal A-type bre...
Dr Timothy J. Whelan - McMaster University, Ontario, Canada
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patient...
Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio,...
Biomarker analysis of the NeoALTTO trial provides oncofertility insight for youn...
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer wi...
Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San ...
ASCO 2022: Breast cancer highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ASCO 2022: Latest in prostate cancer, including PARP inhibitors
Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford
Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of...
Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands